Additional Info: Myasthenia Gravis (MG) is an autoimmune neuromuscular disorder characterized by muscle weakness, most commonly due to autoantibody-mediated loss of functional acetylcholine receptors (AChR) in the neuromuscular junction. AChR-binding autoantibodies are diagnostic of MG, and are found in 85-90% of MG patients. AChR modulating antibodies cross-link AChR molecules on the cell surface, promoting internalization, and decreasing AChR surface density. The AChR binding and modulating antibody assays have similar sensitivities, but performing them together increases the sensitivity of antibody detection by approximately 5%.
Methodology: Radiobinding Assay
Specimen Requirements: 1 yellow-top SST tube (minimum: 0.5 mL of serum). Centrifuge SST 30 minutes after draw. Refrigerate specimen after collection.
Analytical Time:
5-8 days
Days Set Up: Sunday, Tuesday, Thursday
CPT Information:
83519 –